摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苄氧羰基-L-缬氨酰-L-丙氨酸 | 24787-89-1

中文名称
苄氧羰基-L-缬氨酰-L-丙氨酸
中文别名
苄氧羰基-L-缬氨酰胺-L-丙氨酸
英文名称
Z-Val-Ala
英文别名
N-[(benzyloxy)carbonyl]-L-valyl-L-alanine;Z-Val-Ala-OH;(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoic acid
苄氧羰基-L-缬氨酰-L-丙氨酸化学式
CAS
24787-89-1
化学式
C16H22N2O5
mdl
——
分子量
322.361
InChiKey
KDQLNJPBTLIYNW-AAEUAGOBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    165 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
  • 沸点:
    575.5±45.0 °C(Predicted)
  • 密度:
    1.201

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    23
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    105
  • 氢给体数:
    3
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2924299090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    2-8°C,存放在干燥密封的环境中。

SDS

SDS:67c8a7910c96532c8025b5cdbecc04e4
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Z-Val-Ala-OH
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Z-Val-Ala-OH
CAS number: 24787-89-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H22N2O5
Molecular weight: 322.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Z-Val-Ala-OH 是缬氨酸和丙氨酸的二肽衍生物[1]。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity
    作者:BinQing Wei、Janet Gunzner-Toste、Hui Yao、Tao Wang、Jing Wang、Zijin Xu、Jinhua Chen、John Wai、Jim Nonomiya、Siao Ping Tsai、Josefa Chuh、Katherine R. Kozak、Yichin Liu、Shang-Fan Yu、Jeff Lau、Guangmin Li、Gail D. Phillips、Doug Leipold、Amrita Kamath、Dian Su、Keyang Xu、Charles Eigenbrot、Stefan Steinbacher、Rachana Ohri、Helga Raab、Leanna R. Staben、Guiling Zhao、John A. Flygare、Thomas H. Pillow、Vishal Verma、Luke A. Masterson、Philip W. Howard、Brian Safina
    DOI:10.1021/acs.jmedchem.7b01430
    日期:2018.2.8
    Antibody–drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker
    抗体-药物偶联物(ADC)已成为肿瘤学的重要治疗手段,其中三种已获得FDA批准,另外60多项已在临床试验中获得批准。尽管取得了进步,但仍需要改善ADC治疗指数。被溶酶体蛋白酶裂解的基于肽的ADC接头在血清中显示出足够的稳定性,并在靶细胞中有效释放有效负载。如果该接头可以被肿瘤特异性蛋白酶优先水解,则安全系数可能会提高。但是,基于肽的接头的使用限制了我们调节蛋白酶特异性的能力。在这里,我们报告新型非肽类ADC接头的结构指导发现。我们表明,含有环丁烷-1,1-二羧酸的连接子主要被组织蛋白酶B水解,而缬氨酸-瓜氨酸二肽连接子则不被水解。带有非肽接头的ADC在体内与具有二肽接头的ADC一样有效和稳定。我们的结果有力地支持了拟肽连接子的应用,并为改善ADC的选择性提供了新的机会。
  • Facile N-Urethane-Protected α-Amino/Peptide Thioacid Preparation Using EDC and Na2S
    作者:Vommina Sureshbabu、T. Vishwanatha、M. Samarasimhareddy
    DOI:10.1055/s-0031-1290091
    日期:2012.1
    We report herein an efficient protocol for the synthesis of N-urethane-protected α-amino/peptide thioacids from their corresponding acids mediated by EDC and Na2S. The fast reaction under mild conditions enabled the process to be completed in shorter duration with good yield circumventing column purification. The chemistry is compatible with a wide variety of urethane protecting groups, side-chain functionalities, and sterically hindered amino ­acids.
    本文报道了一种高效的方法,通过EDC和Na2S介导,从相应的酸合成N-urethane保护的α-氨基酸/肽硫酸酯。在温和条件下快速反应使得该过程能在较短时间内完成,且产率良好,无需柱层析纯化。该化学方法适用于多种urethane保护基团、侧链功能团以及空间位阻氨基酸。
  • Synthesis of P1 aspartate-based peptide acyloxymethyl and fluoromethyl ketones as inhibitors of interleukin-1β-converting enzyme
    作者:Laszlo Revesz、Chantal Briswalter、Richard Heng、Albert Leutwiler、Rudolf Mueller、Hans-Juerg Wuethrich
    DOI:10.1016/0040-4039(94)88361-0
    日期:1994.12
    Improved procedures have been developed for the synthesis of P1 aspartate-based 2,6-dichlorobenzoyloxymethyl ketone 1 and fluoromethyl ketone 2, the prodrugs of two potent ICE-inhibitors. 1 was prepared from (R)-trans-4,5-O-isopropylidene-4,5-dihydroxy-2-pentenecarboxylic acid ethyl ester; 2 was obtained via a nitro-aldol condensation as key step from in situ generated fluoroacetaldehyde.
    已经开发出用于合成基于天冬氨酸的P1的2,6-二氯苯甲酰氧基甲基酮1和氟甲基酮2的改进方法,这是两种有效的ICE抑制剂的前药。1由(R)-反式-4,5-O-异亚丙基-4,5-二羟基-2-戊烯基羧酸乙酯制备;2从经由硝基-羟醛缩合为关键步骤中获得原位生成fluoroacetaldehyde。
  • Recyclable Hypervalent Iodine(III) Reagent Iodosodilactone as an Efficient Coupling Reagent for Direct Esterification, Amidation, and Peptide Coupling
    作者:Jun Tian、Wen-Chao Gao、Dong-Mei Zhou、Chi Zhang
    DOI:10.1021/ol301085v
    日期:2012.6.15
    hypervalent iodine(III) reagent plays a novel role as an efficient coupling reagent to promote the direct condensation between carboxylic acids and alcohols or amines to provide esters, macrocyclic lactones, amides, as well as peptides without racemization. The regeneration of iodosodilactone (1) can also be readily achieved. The intermediate acyloxyphosphonium ion C from the activation of a carboxylic acid
    高价碘(III)试剂在促进羧酸与醇或胺之间的直接缩合以提供酯,大环内酯,酰胺以及未经消旋化作用的肽方面起着新颖的作用,可促进羧酸与醇或胺之间的直接缩合。碘代二内酯(1)的再生也可以容易地实现。据认为,来自羧酸活化的中间体酰氧基phosph离子C参与了本酯化反应。
  • Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1
    作者:Aaron D. Krabill、Hao Chen、Sajjad Hussain、Chad S. Hewitt、Ryan D. Imhoff、Christine S. Muli、Chittaranjan Das、Paul J. Galardy、Michael K. Wendt、Daniel P. Flaherty
    DOI:10.3390/molecules26051227
    日期:——
    this end a study was carried out to fully characterize and optimize the irreversible covalent UCHL1 inhibitor VAEFMK. Structure-activity relationship studies identified modifications to improve activity versus the target and a full cellular characterization was carried out for the first time with this scaffold. The studies produced a new inhibitor, 34, with an IC50 value of 7.7 µM against UCHL1 and no
    去泛素化酶 (DUB) UCHL1 与多种疾病状态有关,包括神经退行性疾病和癌症。然而,缺乏高质量的探针分子来更好地了解 UCHL1 生物学。为此,我们进行了一项研究,以全面表征和优化不可逆共价 UCHL1 抑制剂 VAEFMK。结构-活性关系研究确定了修饰以提高相对于靶标的活性,并且首次使用该支架进行了完整的细胞表征。研究产生了一种新的抑制剂34,其针对 UCHL1 的 IC 50值为 7.7 µM,与最接近的相关 DUB UCHL3 相比没有可观察到的活性。该分子还能够选择性抑制细胞中的 UCHL1,并且没有表现出任何明显的脱靶毒性。最后,该分子被用于初步探针研究,以评估 UCHL1 在骨髓瘤细胞增殖和小细胞肺癌细胞迁移行为中的作用,从而使34成为用于 UCHL1 生物学评估的新工具。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物